ALN-6222 (INHBE) Overview

An Investigational RNAi Therapeutic

Disease State(s) Under Investigation	Obesity & weight management[1,3]
MoA	Designed to target inhibin E (INHBE)[2]
Route of Administration	Subcutaneous[1]

Clinical Trials Overview

Phase 1	Treatment Arms	Primary Endpoint
Recruiting ⏳		
Safety, Tolerability, Efficacy, PK, and PD of **ALN-6222** Adult Patients With Obesity[1]	ALN-6222; placebo	Safety (frequency of AEs)

The safety and efficacy of ALN-6222 (INHBE) has not been established by any health authority.

AE, adverse event ; MoA, mechanism of action; PD, pharmacodynamics; PK, pharmacokinetics; RNA, ribonucleic acid; RNAi, RNA interference. 1. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07624071 (Accessed July 29, 2026). 2. Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress. Press Release. Alnylam Pharmaceuticals, Inc. https://investors.alnylam.com/press-release?id=29986 Updated July 30, 2026. Accessed July 31, 2026. 3. Alnylam.com. 2026. https://www.alnylam.com/alnylam-rnai-pipeline (Accessed September 3, 2026).

Alnylam